Lipopolysaccharide induces steroid-resistant exacerbations in a mouse model of allergic airway disease collectively through IL-13 and pulmonary macrophage activation

Clin Exp Allergy. 2020 Jan;50(1):82-94. doi: 10.1111/cea.13505. Epub 2019 Oct 18.

Abstract

Background: Acute exacerbations of asthma represent a major burden of disease and are often caused by respiratory infections. Viral infections are recognized as significant triggers of exacerbations; however, less is understood about the how microbial bioproducts such as the endotoxin (lipopolysaccharide (LPS)) trigger episodes. Indeed, increased levels of LPS have been linked to asthma onset, severity and steroid resistance.

Objective: The goal of this study was to identify mechanisms underlying bacterial-induced exacerbations by employing LPS as a surrogate for infection.

Methods: We developed a mouse model of LPS-induced exacerbation on the background of pre-existing type-2 allergic airway disease (AAD).

Results: LPS-induced exacerbation was characterized by steroid-resistant airway hyperresponsiveness (AHR) and an exaggerated inflammatory response distinguished by increased numbers of infiltrating neutrophils/macrophages and elevated production of lung inflammatory cytokines, including TNFα, IFNγ, IL-27 and MCP-1. Expression of the type-2 associated inflammatory factors such as IL-5 and IL-13 were elevated in AAD but not altered by LPS exposure. Furthermore, AHR and airway inflammation were no longer suppressed by corticosteroid (dexamethasone) treatment after LPS exposure. Depletion of pulmonary macrophages by administration of 2-chloroadenosine into the lungs suppressed AHR and reduced IL-13, TNFα and IFNγ expression. Blocking IL-13 function, through either IL-13-deficiency or administration of specific blocking antibodies, also suppressed AHR and airway inflammation.

Conclusions & clinical relevance: We present evidence that IL-13 and innate immune pathways (in particular pulmonary macrophages) contribute to LPS-induced exacerbation of pre-existing AAD and provide insight into the complex molecular processes potentially underlying microbial-induced exacerbations.

Keywords: IL-13; Macrophages; airway hyperresponsiveness; asthma exacerbation; lipopolysaccharide; steroid resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Airway Resistance / drug effects
  • Animals
  • Asthma / immunology*
  • Bacterial Infections
  • Bronchoalveolar Lavage Fluid / cytology
  • Chemokine CCL2
  • Cytokines / drug effects
  • Cytokines / immunology
  • Dexamethasone / pharmacology*
  • Disease Models, Animal
  • Disease Progression
  • Drug Resistance
  • Glucocorticoids / pharmacology*
  • Interferon-gamma / drug effects
  • Interferon-gamma / immunology
  • Interleukin-13 / immunology*
  • Interleukins / immunology
  • Lipopolysaccharides / pharmacology*
  • Macrophage Activation / drug effects
  • Macrophage Activation / immunology*
  • Macrophages, Alveolar / drug effects
  • Macrophages, Alveolar / immunology*
  • Mice
  • Mucin 5AC / drug effects
  • Mucin 5AC / metabolism
  • Ovalbumin
  • Respiratory Hypersensitivity / immunology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Necrosis Factor-alpha / drug effects
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Cytokines
  • Glucocorticoids
  • IFNG protein, mouse
  • Il27 protein, mouse
  • Interleukin-13
  • Interleukins
  • Lipopolysaccharides
  • Muc5ac protein, mouse
  • Mucin 5AC
  • Tnf protein, mouse
  • Tumor Necrosis Factor-alpha
  • Dexamethasone
  • Interferon-gamma
  • Ovalbumin

Grants and funding